Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Bone Marrow Transplant ; 33(12): 1173-9, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15094754

ABSTRACT

We conducted a nationwide survey to define incidence of deep fungal infections and fungal prophylaxis practices after HSCT. In all, 63 institutions responded. Total number of in-patient transplantations was 935: 367 autologous, 414 allogeneic myeloablative, and 154 allogeneic reduced-intensity (RIST) (n=154). Number of patients who were cared for in a clean room at transplant was 261 (71%) in autologous, 409 (99%) in conventional and 93 (66%) in RIST, respectively. All patients received prophylactic antifungal agents; 89% fluconazole. Number of patients who received the dosage recommended in the CDC guidelines (400 mg/day) was 135 (42%) in conventional transplant and 34 (30%) in RIST (P=0.037). Number of patients who received fluconazole until engraftment and beyond day 75 in conventional transplant vs RIST was, respectively, 324 (100%) vs 109 (97%), and 39 (12%) vs 18 (16%), with no significant difference between the two groups. A total of 37 patients (4.0%) were diagnosed with deep fungal infections; autologous transplantation (0.03%), conventional transplantation (6.0%) and RIST (7.1%). Wide variations in antifungal prophylaxis practice according to the type of transplant and the institutions, and deep fungal infection remain significant problems in RIST.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Mycoses/epidemiology , Mycoses/prevention & control , Premedication/statistics & numerical data , Antifungal Agents/therapeutic use , Data Collection , Fluconazole/therapeutic use , Hematologic Diseases/complications , Hematologic Diseases/therapy , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cell Transplantation/statistics & numerical data , Humans , Incidence , Japan , Mycoses/drug therapy , Practice Guidelines as Topic , Retrospective Studies , Transplantation Conditioning/methods , Transplantation Conditioning/statistics & numerical data , Transplantation, Autologous/statistics & numerical data , Transplantation, Homologous/statistics & numerical data
2.
Gene Ther ; 11(9): 784-90, 2004 May.
Article in English | MEDLINE | ID: mdl-14961067

ABSTRACT

Sendai virus (SeV) vector-mediated gene delivery of glial cell line-derived neurotrophic factor (GDNF) and nerve growth factor (NGF) prevented the delayed neuronal death induced by transient global ischemia in gerbils, even when the vector was administered several hours after ischemia. Intraventricular administration of SeV vector directed high-level expression of the vector-encoded neurotrophic factor genes, which are potent candidates for the treatment of neurodegenerative diseases. After occlusion of the bilateral carotid arteries of gerbils, SeV vector carrying GDNF (SeV/GDNF), NGF (SeV/NGF), brain-derived neurotrophic factor (SeV/BDNF), insulin-like growth factor-1 (SeV/IGF-1) or vascular endothelial growth factor (SeV/VEGF) was injected into the lateral ventricle. Administration of SeV/GDNF, SeV/NGF or SeV/BDNF 30 min after the ischemic insult effectively prevented the delayed neuronal death of the hippocampal CA1 pyramidal neurons. Furthermore, the administration of SeV/GDNF or SeV/NGF as late as 4 or 6 h after the ischemic insult also prevented the death of these neurons. These results indicate that SeV vector-mediated gene transfer of neurotrophic factors has high therapeutic potency for preventing the delayed neuronal death induced by transient global ischemia, and provides an approach for gene therapy of stroke.


Subject(s)
Brain Ischemia/therapy , Genetic Therapy/methods , Nerve Growth Factor/genetics , Neurons/pathology , Animals , Brain Ischemia/metabolism , Brain Ischemia/pathology , Cell Death/genetics , Gene Transfer Techniques , Gerbillinae , Glial Cell Line-Derived Neurotrophic Factor , Hippocampus/metabolism , Nerve Growth Factor/metabolism , Nerve Growth Factors/genetics , Nerve Growth Factors/metabolism , Sendai virus/genetics
3.
Gene ; 275(1): 141-8, 2001 Sep 05.
Article in English | MEDLINE | ID: mdl-11574162

ABSTRACT

Here we purified and identified a myosin II kinase from sea urchin eggs. The activity of this myosin II kinase in the egg extract was not significantly affected by Ca(2+)/calmodulin (CaM). Using sequential column chromatographies, we purified the myosin II kinase from the egg extract as a complex composed of 36- (p36) and 28-kDa (p28) proteins. Partial amino acid sequences of these two components were highly coincident with those of the alpha and beta subunits of protein kinase CK2 (formerly casein kinase II) in sea urchin eggs, respectively. To confirm that the purified myosin II kinase was CK2, we obtained a cDNA which encodes p36 from a cDNA library of sea urchin eggs. The amino acid sequence derived from the obtained cDNA showed over 70% homology to CK2 from various eukaryotes. Furthermore, recombinant p36, as well as the purified myosin II kinase, phosphorylated MRLC. One dimensional phosphopeptide mapping revealed that the phosphorylation site(s) of MRLC by both recombinant p36 and the purified myosin II kinase was identical. These clearly showed that the Ca(2+)/CaM-independent myosin II kinase activity in sea urchin eggs was identical to CK2.


Subject(s)
Ovum/metabolism , Protein Serine-Threonine Kinases/genetics , Sea Urchins/genetics , Amino Acid Sequence , Animals , Base Sequence , Casein Kinase II , Cell-Free System/enzymology , DNA, Complementary/chemistry , DNA, Complementary/genetics , Electrophoresis, Polyacrylamide Gel , Female , HeLa Cells , Humans , Molecular Sequence Data , Myosin Light Chains/metabolism , Myosins/metabolism , Ovum/enzymology , Phosphorylation , Protein Serine-Threonine Kinases/isolation & purification , Protein Serine-Threonine Kinases/metabolism , Sea Urchins/enzymology , Sequence Alignment , Sequence Analysis, DNA , Sequence Homology, Amino Acid
4.
Gene Ther ; 8(14): 1043-50, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11526451

ABSTRACT

We scrutinized the applicability and efficacy of Sendai virus (SeV) vectors expressing either LacZ or human insulin-like growth factor-I (hIGF-I) in gene transfer into skeletal muscle. Seven days after the intramuscular injection of LacZ/SeV X-gal labeled myofibers were demonstrated in rat anterior tibialis muscle with/without bupivacaine treatment and the transgene expression persisted up to 1 month after injection. Recombinant hIGF-I was detected as a major protein species in culture supernatants of a neonatal rat myoblast cell line L6 and thus induced the cells to undergo myogenetic differentiation. The introduction of hIGF-I/SeV into the muscle showed a significant increase in regenerating and split myofibers which were indicative of hypertrophy, and also an increase in the total number of myofibers, in comparison to that seen in the LacZ/SeV-treated control muscle. These results demonstrate that SeV achieves high-level transgene expression in skeletal muscle, and that hIGF-I gene transfer using SeV vector may therefore have great potential in the treatment of neuromuscular disorders.


Subject(s)
Genetic Therapy/methods , Genetic Vectors/administration & dosage , Insulin-Like Growth Factor I/genetics , Muscle, Skeletal/physiology , Neuromuscular Diseases/therapy , Regeneration , Animals , Cells, Cultured , Gene Expression , Hindlimb , Humans , Injections, Intramuscular , Insulin-Like Growth Factor I/analysis , Lac Operon , Male , Models, Animal , Rats , Rats, Sprague-Dawley , Recombinant Proteins/analysis , Respirovirus/genetics , Transfection/methods , Transgenes
5.
Talanta ; 46(6): 1293-7, 1998 Aug.
Article in English | MEDLINE | ID: mdl-18967256

ABSTRACT

The concentration of potassium was determined by a combination of flow injection analysis (FIA) with an all-solid-state potassium sensor detection. The all-solid-state potassium-selective electrode possessing long-term potential stability was fabricated by coating an electroactive polypyrrole/poly(4-styrenesulfonate) film electrode with a plasticized poly(vinyl chloride) membrane containing valinomycin. The simple FIA system developed in this laboratory demonstrated sensitivity identical to that in the batch system and achieved considerably rapid assay (150 samples h(-1)). Analyses of soy sauce and control serum samples by this FIA system yielded results in good agreement with those obtained by conventional measurements.

SELECTION OF CITATIONS
SEARCH DETAIL
...